AR002255A1 - Una composicion que comprende una formulacion de antigeno microfluidizada y usos de dicha formulacion. - Google Patents

Una composicion que comprende una formulacion de antigeno microfluidizada y usos de dicha formulacion.

Info

Publication number
AR002255A1
AR002255A1 AR10045895A AR10045895A AR002255A1 AR 002255 A1 AR002255 A1 AR 002255A1 AR 10045895 A AR10045895 A AR 10045895A AR 10045895 A AR10045895 A AR 10045895A AR 002255 A1 AR002255 A1 AR 002255A1
Authority
AR
Argentina
Prior art keywords
formulation
antigen
ctl
providing
response
Prior art date
Application number
AR10045895A
Other languages
English (en)
Original Assignee
Idec Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idec Pharma Corp filed Critical Idec Pharma Corp
Publication of AR002255A1 publication Critical patent/AR002255A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Detergent Compositions (AREA)

Abstract

Métodos y composiciones útiles para la inducción de una respuesta citotóxica del linfocito-T (CTL) en un ser humano o en un animal domesticado oun animal importante de labranza. El método incluye los pasos de proporcionar el antígeno ene l cual se desea que se produzca la respuesta CTL y proporcionaruna formulación de antígeno que consiste esencialmente en dos o más de: un detergente estabilizante, un agente de formación de micela y un aceite. Estaformulación de antígeno,prefer iblemente, carece de un componente péptido inmunoestimulante, o tiene niveles suficientemente bajos de dicho componentecomo para no reducir la respuesta CTL deseada. Esta formulación se proporciona como una emulsión estable de aceiteen agua. La invención se refiere también amétodos para tratar pacientes infectados con virus HIV, de malaria;de hepatitis ; de herpes; de la gripe; de virus sincitial respiratorio o que sufren cáncer.
AR10045895A 1994-12-07 1995-12-06 Una composicion que comprende una formulacion de antigeno microfluidizada y usos de dicha formulacion. AR002255A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/351,001 US5709860A (en) 1991-07-25 1994-12-07 Induction of cytotoxic T-lymphocyte responses

Publications (1)

Publication Number Publication Date
AR002255A1 true AR002255A1 (es) 1998-03-11

Family

ID=23379172

Family Applications (1)

Application Number Title Priority Date Filing Date
AR10045895A AR002255A1 (es) 1994-12-07 1995-12-06 Una composicion que comprende una formulacion de antigeno microfluidizada y usos de dicha formulacion.

Country Status (33)

Country Link
US (2) US5709860A (es)
EP (1) EP0801656A4 (es)
JP (1) JPH10510264A (es)
CN (2) CN1109046C (es)
AP (1) AP661A (es)
AR (1) AR002255A1 (es)
AU (1) AU699044B2 (es)
BG (1) BG63262B1 (es)
BR (1) BR9509872A (es)
CA (1) CA2204738A1 (es)
CZ (1) CZ293439B6 (es)
EE (1) EE03569B1 (es)
FI (1) FI972431A0 (es)
GE (1) GEP20012556B (es)
HK (1) HK1008226A1 (es)
HU (1) HUP9800946A2 (es)
IS (1) IS4479A (es)
LT (1) LT4308B (es)
LV (1) LV11866B (es)
MD (1) MD1586G2 (es)
MX (1) MX9704097A (es)
NO (1) NO972521L (es)
NZ (1) NZ298582A (es)
OA (1) OA10736A (es)
PL (1) PL183954B1 (es)
RO (1) RO120065B1 (es)
RU (1) RU2201253C2 (es)
SI (1) SI9520148A (es)
SK (1) SK71397A3 (es)
TJ (1) TJ384B (es)
TW (1) TW487575B (es)
UA (1) UA49814C2 (es)
WO (1) WO1996017863A1 (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197311B1 (en) * 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
CA2142007C (en) * 1992-08-11 2007-10-30 Robert Glen Urban Immunomodulatory peptides
ZA988461B (en) * 1997-09-18 1999-03-30 Idec Pharma Corp Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6183746B1 (en) * 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
FR2771640B1 (fr) 1997-12-03 2000-02-11 Inst Nat Sante Rech Med Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques
AU3344299A (en) * 1998-04-20 1999-11-08 Shionogi & Co., Ltd. Th2-migration promoters containing w/o emulsions
US20010033839A1 (en) * 1999-10-04 2001-10-25 Emilio Barbera-Guillem Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation
WO2000049655A1 (en) 1999-02-18 2000-08-24 Seiko Epson Corporation Semiconductor device, circuit board, method of manufacturing circuit board, and electronic device
ATE403436T1 (de) * 1999-03-24 2008-08-15 Secr Defence Polykationische karbohydrate als immunostimulierende mittel in impstoffen
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
FR2805163A1 (fr) * 2000-02-21 2001-08-24 Pf Medicament Utilisation d'un detergent de type zwittergent pour la preparation d'une composition pharmaceutique destinee a etre administree par voie nasale
WO2001098206A1 (en) * 2000-06-22 2001-12-27 Rxkinetix, Inc. Delivery vehicle composition and methods for delivering antigens and other drugs
FR2814957B1 (fr) * 2000-10-06 2002-12-20 Aventis Pasteur Composition vaccinale et procede de stabilisation
WO2003104429A2 (en) * 2002-06-10 2003-12-18 Idec Pharmaceuticals Corporation Genes overexpressed by ovarian cancer and their use in developing novel therapeutics
WO2004012751A1 (ja) * 2002-08-02 2004-02-12 Sumitomo Pharmaceuticals Company, Limited 細菌細胞壁骨格成分製剤
JP2006516883A (ja) 2002-09-19 2006-07-13 アメリカ合衆国 Ｐ．アリアシポリペプチド、ユウガイサシチョウバエポリペプチド、および使用法
WO2004037175A2 (en) * 2002-10-21 2004-05-06 Mgi Pharma Biologics, Inc. Compositions and methods for treating human papillomavirus-mediated disease
US7485306B2 (en) 2002-10-29 2009-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Lutzomyia longipalpis polypeptides and methods of use
US20080032384A1 (en) * 2004-04-22 2008-02-07 Takehiko Nomura Pharmaceutical Preparation Containing Bacterial Cell Wall Skeleton
WO2008039171A2 (en) 2005-08-08 2008-04-03 Oregon Health & Science University Inactivating pathogens with hydrogen peroxide for vaccine production
US20100130425A1 (en) 2005-09-09 2010-05-27 Oregon Health & Science University Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia
US7732166B2 (en) * 2005-11-15 2010-06-08 Oncohealth Corporation Detection method for human pappilomavirus (HPV) and its application in cervical cancer
EP2397853B1 (en) 2006-03-14 2014-01-15 Oregon Health and Science University Methods for detecting a mycobacterium tuberculosis infection
CA2646319A1 (en) 2006-04-20 2007-11-01 The Henry M. Jackson Foundation For The Advancement Of Military Medicine , Incorporated Methods and compositions based on shiga toxin type 1 protein
US8968995B2 (en) * 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
US8859218B2 (en) * 2008-06-13 2014-10-14 Oncohealth Corp. In situ detection of early stages and late stages HPV infection
WO2008106551A2 (en) 2007-02-28 2008-09-04 The Govt. Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Serv. Brachyury polypeptides and methods for use
EP2324049B1 (en) 2008-08-04 2016-05-25 The Government of the U.S.A. as represented by The Secretary of the dept. of Health & Human Services Membrane proximal region of hiv gp41 anchored to the lipid layer of a virus-like particle vaccine
US8664183B2 (en) 2009-02-27 2014-03-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services SPANX-B polypeptides and their use
CN102449479B (zh) 2009-05-07 2015-11-25 安科健康公司 鉴别高度或≥cin2用于人***瘤病毒(hpv)与hpv相关癌症的早期及晚期检测、筛检和诊断
WO2011041886A1 (en) 2009-10-07 2011-04-14 University Of Victoria Innovation And Development Corporation Vaccines comprising heat-sensitive transgenes
US9181306B2 (en) 2009-10-16 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
US8961989B2 (en) 2009-11-20 2015-02-24 Oregon Health & Science University Methods for producing an immune response to tuberculosis
WO2011084598A1 (en) 2010-01-08 2011-07-14 Oncohealth Corporation High throughput cell-based hpv immunoassays for diagnosis and screening of hpv-associated cancers
WO2011112599A2 (en) 2010-03-12 2011-09-15 The United States Of America, As Represented By The Secretary. Department Of Health & Human Services Immunogenic pote peptides and methods of use
EP3187585A1 (en) 2010-03-25 2017-07-05 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
CN102125698A (zh) * 2010-11-29 2011-07-20 昆明理工大学 具有正常免疫功能的小鼠移植肿瘤模型的建立方法
WO2012170765A2 (en) 2011-06-10 2012-12-13 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
HUE053664T2 (hu) 2011-07-18 2021-07-28 The United States Of America Eljárások és készítmények Polyomavírussal összefüggõ betegségek gátlására
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
WO2013152352A1 (en) 2012-04-06 2013-10-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Live, attenuated rubella vector to express vaccine antigens
NZ701881A (en) 2012-05-16 2016-10-28 Immune Design Corp Vaccines for hsv-2
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
WO2014043518A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
US20150283220A1 (en) 2012-10-19 2015-10-08 Bavarian Nordic, Inc. Methods and compositions for the treatment of cancer
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
JP6758185B2 (ja) 2013-12-13 2020-09-23 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ マルチエピトープｔａｒｐペプチドワクチンおよびその使用
WO2015095770A1 (en) 2013-12-20 2015-06-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic jc polyomavirus compositions and methods of use
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
KR20180057610A (ko) 2015-08-03 2018-05-30 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 브라큐리 결실 돌연변이체, 브라큐리 결실 돌연변이체를 인코딩하는 비-효모 벡터, 및 이들의 용도
CN115354025A (zh) * 2016-03-17 2022-11-18 伯克利之光生命科技公司 微流体装置中t淋巴细胞的选择和克隆
AU2017261705B2 (en) 2016-05-10 2024-04-18 Najit Technologies, Inc. Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production
EP3703745B1 (en) 2017-11-04 2024-04-10 Nevada Research & Innovation Corporation Immunogenic conjugates and methods of use thereof
CN113454100A (zh) 2018-12-04 2021-09-28 洛克菲勒大学 Hiv疫苗免疫原
TW202214294A (zh) 2020-09-30 2022-04-16 美商碩騰服務公司 具有ｈｙａＣ及ｎａｎＰ缺失之新穎多殺性巴斯德氏菌株及疫苗

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117113A (en) * 1974-06-25 1978-09-26 National Research Development Corporation Immunological preparations
GB1502774A (en) * 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
US4770874A (en) * 1983-08-22 1988-09-13 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
JPS6147500A (ja) * 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
US5114708A (en) * 1985-06-18 1992-05-19 Emory University Method for stimulating growth in animals
US5234683A (en) * 1985-06-18 1993-08-10 Emory University Method of stimulating the immune system
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
WO1988002634A1 (en) * 1986-10-20 1988-04-21 Chiron Corporation Vaccine for use in the therapeutic treatment of hsv
US4778784A (en) * 1987-01-07 1988-10-18 Baylor College Of Medicine Cyclic peptide and method of use for inducing an immunological response to hepatitis B virus
US4963354A (en) * 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
DE3855807T2 (de) * 1987-11-03 1997-06-12 Syntex (U.S.A.) Inc., Palo Alto, Calif. Einen Tetra-Polyol enthaltendes Impfstoff-Adjuvans
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
CA2017507C (en) * 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
DE4018442A1 (de) * 1990-06-08 1991-12-12 Boehringer Mannheim Gmbh Rekombinante dna und verfahren zur herstellung chimaerer antikoerper
AU1025692A (en) * 1991-02-06 1992-08-13 Ciba-Geigy Ag Novel chimeric antiidiotypic monoclonal antibodies
EP0596032B2 (en) * 1991-07-25 2004-04-07 Idec Pharmaceuticals Corporation Induction of cytotoxic t-lymphocyte responses
DE4443414A1 (de) * 1994-12-07 1996-06-13 Basf Ag Benzopyranfarbstoffe und deren Zwischenprodukte
US7735069B2 (en) 2006-02-09 2010-06-08 International Business Machines Corporation Creating software debug breakpoints activated by specific call patterns
US8919787B1 (en) 2010-10-08 2014-12-30 James Timothy Wilcher Reciprocating tool attachment assembly and methods

Also Published As

Publication number Publication date
MD1586G2 (ro) 2001-10-31
CA2204738A1 (en) 1996-06-13
AP661A (en) 1998-08-19
BG101656A (en) 1998-02-27
TJ384B (en) 2004-07-08
CN1515319A (zh) 2004-07-28
OA10736A (en) 2002-12-11
PL183954B1 (pl) 2002-08-30
LV11866B (en) 1998-01-20
PL320612A1 (en) 1997-10-13
EE03569B1 (et) 2001-12-17
AP9701056A0 (en) 1997-10-31
LV11866A (lv) 1997-10-20
MD1586F2 (en) 2001-01-31
FI972431A (fi) 1997-06-06
TW487575B (en) 2002-05-21
GEP20012556B (en) 2001-10-25
HUP9800946A2 (hu) 1998-07-28
RO120065B1 (ro) 2005-08-30
BR9509872A (pt) 1997-11-25
US5709860A (en) 1998-01-20
NO972521D0 (no) 1997-06-03
EP0801656A4 (en) 2004-06-30
NZ298582A (en) 1999-10-28
IS4479A (is) 1997-05-07
HK1008226A1 (en) 1999-05-07
LT97115A (en) 1997-11-25
MD970199A (en) 1999-02-28
CZ293439B6 (cs) 2004-04-14
AU699044B2 (en) 1998-11-19
LT4308B (lt) 1998-03-25
AU4410496A (en) 1996-06-26
EP0801656A1 (en) 1997-10-22
BG63262B1 (bg) 2001-07-31
CZ174197A3 (en) 1997-10-15
UA49814C2 (uk) 2002-10-15
CN1109046C (zh) 2003-05-21
SK71397A3 (en) 1997-11-05
US5695770A (en) 1997-12-09
SI9520148A (sl) 1998-06-30
JPH10510264A (ja) 1998-10-06
WO1996017863A1 (en) 1996-06-13
EE9700100A (et) 1997-10-15
MX9704097A (es) 1998-07-31
RU2201253C2 (ru) 2003-03-27
CN1175260A (zh) 1998-03-04
FI972431A0 (fi) 1997-06-06
NO972521L (no) 1997-08-06

Similar Documents

Publication Publication Date Title
AR002255A1 (es) Una composicion que comprende una formulacion de antigeno microfluidizada y usos de dicha formulacion.
ES2117052T3 (es) Induccion de respuestas de linfocitos t citotoxicos.
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
BRPI0108449B8 (pt) formulações de pasta aperfeiçoada, suas aplicações farmacêuticas, método para matar insetos, bem como processo para preparar as referidas formulações
UA66744C2 (en) 5,6-dichlorobenzimidazole derivatives, methods for the preparation thereof, pharmaceutical composition and method for treatment of viral infections
DE69114498D1 (de) Kurzbettige, einfach ungesättigte fettsäuren enthaltende nahrungsmittel und pharmazeutische zusammensetzungen sowie deren anwendungen.
MX9204885A (es) Composicion de vacuna que comprende virus del sindrome de infertilidad y respiratorio de los cerdos.
BR0311939A (pt) composição farmacêutica, método para tratar inflamação em um mamìfero e uso de uma citocina protetora de tecido orgánico
TR199903053T2 (xx) Benzimidazol t�revleri.
CO4790100A1 (es) Composicion cinergetica y metodos para tratar crecimientos neoplasicos o cancerosos y para restaurar o estimular hema- topoiesis
ES2103276T3 (es) Composicion para la activacion del sistema inmunitario.
ES2093269T3 (es) Microemulsiones del tipo agua en aceite.
IL106968A0 (en) Potentiation of immunogenic response
PE20040103A1 (es) Metodo y formas de dosificacion para incrementar la solubilidad de composiciones de farmaco para administracion controlada
NO874150D0 (no) Preparater inneholdende propylenglykol og/eller polyetylenglykol og urinstoff som aktive hovedkomponenter og anvendelse derav.
BRPI0414320A (pt) composição para tratamento da pele
AR008799A1 (es) Composicion de vacuna para prevenir o tratar el paludismo; uso de dicha composicion para elaborar medicamentos y metodo para dicha profilaxis y dichotratamiento
MX17808A (es) Nuevos derivados de artemisinina,procedimiento para su preparacion y su uso como agentes antiprosoos
ES2185760T3 (es) Composicion farmaceutica para el tratamiento del herpes.
FI972054A (fi) Immunogeenisiä koostumuksia
BR9916893A (pt) Tratamento
BR0016304A (pt) Formulação de solução aquosa de interferon estável, método de preparação e usos para a mesma
MX9805441A (es) Compuestos terapeuticos.
ES2119779T3 (es) Solubilizacion de proteinas en formas activas.
ATE342065T1 (de) Impfstofformulierung gegen tuberkulose mit monoglyceriden oder fettsäuren als adjuvant

Legal Events

Date Code Title Description
FG Grant, registration